Biotech Hot Stocks – DNDN, GILD, AMGN, CLSN
Houston, TX – February 5, 2013 — (Net PR News) – AnotherWinningTrade.com delivers quality trading ideas for the elite investor that has the financial wherewithal and market nimbleness to profit on small moves in a stock’s price. Become a member and you will be provided with real-time alerts intended to provide you with the opportunity to make profitable trades. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Stocks that are being watched this morning are: NASDAQ:DNDN, NASDAQ:GILD, NASDAQ:AMGN, NASDAQ:CLSN
Dendreon Corporation (NASDAQ:DNDN) declared that, to review its financial results for the fourth quarter and fiscal year 2012, on Monday, February 25, 2013, at 9:00 a.m. ET/6:00 a.m. PT, the company’s management will present a conference call.
Get A Free Report And Detailed Analysis On DNDN. CLICK HERE To Read
Dendreon Corporation, during the previous trading session, the stock showed a positive movement of 2.02%. Currently, the company has a market capitalization of $936.70 million. The stock’s closing price was $6.07, while it started its day-trade at $5.90. Its 52-week price range was $3.69 – $17.04. If we look at the previous six month’s performance of the stock, it remained optimistic with the gain of 36.4%. In its last one month’s trade it gained 1%.
Gilead Sciences, Inc. (NASDAQ:GILD) remained among the day gainers and traded with volume of 12,765,200 shares in the last trading session, as compared to average volume of 8.60 million shares.
The stock on Monday decreased -2.39% and finished the day at $39.59. GILD was a decliner in the 5 days activity and slipped about -0.23%. The 52 week range of the stock remained $21.91 – $41.14. The one month performance of stock was positive and it scored more than 4%.
How Should Investors React To GILD Now? Find Out In This TREND ANALYSIS REPORT
Amgen, Inc. (NASDAQ:AMGN) reported that, on Thursday, Feb. 7, 2013, in New York City, at the Mandarin Oriental Hotel, 80 Columbus Circle, at 8 a.m. Eastern Standard Time, it will hold its Meeting to provide its Business Review.
Amgen, Inc. traded with a drop of -0.65% and closed at $85.74 after gaining total volume of 3,907,500 shares. Its opening price was $85.44.
How Should Investors Trade AMGN Now? Don’t Trade AMGN Until You Read This TREND ANALYSIS REPORT
If we look at the previous six month’s performance of the stock, it remained optimistic with the gain of 4.29%. In its last one month’s trade it plunged -3.64%. Amgen’s earnings per share is $5.52, while its beta value stands at 0.39 times. AMGN has total market capitalization of $64.82 billion with a total of 756.00 million outstanding shares.
Celsion Corporation (NASDAQ:CLSN) opened at the price of $1.18, whereas its previous closing price was recorded at $1.17. Total volume of the stock was 10,474,700 shares during last trade, while its average volume is 4.34 million shares.
Can CLSN Extend This Gain? Find Out In This TREND ANALYSIS REPORT
The Company’s total market capitalization stands at $40.97 million, along with 35.01 million outstanding shares. CLSN decreased -11.36% and traded within the range of $1.13 – $1.23 for the day. The 52 week range of the stock remained in between $1.13 – $9.44.
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.